Top R&D Stories of 2023
Welcome to the cutting-edge world of research and development as we unveil the Top R&D Stories of 2023 – Oxford Global’s yearly eBook.
Through captivating articles, insight pieces, spotlight interviews, we delve into the remarkable innovations, breakthroughs, and scientific marvels that have defined the landscape of research over the past year. From groundbreaking discoveries in using AI/ML in digital pathology; data management strategies in pharma and precision genome editing through to inhaled drugs development & mRNA manufacturing.
In a world where progress is fuelled by intellectual curiosity and the relentless pursuit of innovation, the Top R&D Stories of 2023 encapsulate the spirit of exploration and the quest for improvement. Join us as we explore the tales of brilliant minds, visionary projects, and the exceptional endeavours that have shaped the future across various domains.
As we navigate through these narratives, you’ll encounter the incredible tales behind the inventions, unveil the intricacies of scientific methodologies, and witness the collaborative efforts that lead to groundbreaking results in biologics, biomarkers, drug discovery, formulation & drug delivery, cell & gene therapies, immune-oncology & multi-omics.
Whether you are a seasoned scientist, an avid technology enthusiast, or simply someone with a curious mind, this eBook promises to inspire, inform, and ignite your passion for the limitless possibilities that research and development hold.
The Top R&D Stories of 2023 by Oxford Global invite you to embark on an enlightening journey, exploring the forefront of human achievement and the exciting prospects that lie ahead.
Contents
As part of a collection of 30+ of our favourite articles from 2023, the Biomarkers section of the eBook covers:
- AI in Digital Pathology: The Applications of Explainable AI & Deep Learning Approaches
- Interview with Simon Gao, Clinical Imaging Scientist at Genentech
- Neurodegenerative Biomarkers & Treatment Strategies
- Predicting Parkinson’s Disease with Machine Learning
- What Makes Biomarkers Hard to Commercialise?
